Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Shalin Kothari, Jens Hillengass, Philip L. McCarthy, Sarah A. Holstein

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. Recent Findings: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Summary: Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 15 2019

Fingerprint

Residual Neoplasm
Multiple Myeloma
Clinical Trials
Disease-Free Survival
Biomarkers
Bone Marrow Diseases
Aptitude
Flow Cytometry
Bone Marrow

Keywords

  • Minimal residual disease
  • Multiple myeloma
  • Overall survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Determination of Minimal Residual Disease in Multiple Myeloma : Does It Matter? / Kothari, Shalin; Hillengass, Jens; McCarthy, Philip L.; Holstein, Sarah A.

In: Current Hematologic Malignancy Reports, Vol. 14, No. 1, 15.02.2019, p. 39-46.

Research output: Contribution to journalReview article

Kothari, Shalin ; Hillengass, Jens ; McCarthy, Philip L. ; Holstein, Sarah A. / Determination of Minimal Residual Disease in Multiple Myeloma : Does It Matter?. In: Current Hematologic Malignancy Reports. 2019 ; Vol. 14, No. 1. pp. 39-46.
@article{5a6150d93669412bac96c385c30571fb,
title = "Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?",
abstract = "Purpose of Review: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. Recent Findings: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Summary: Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.",
keywords = "Minimal residual disease, Multiple myeloma, Overall survival",
author = "Shalin Kothari and Jens Hillengass and McCarthy, {Philip L.} and Holstein, {Sarah A.}",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s11899-019-0497-7",
language = "English (US)",
volume = "14",
pages = "39--46",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Determination of Minimal Residual Disease in Multiple Myeloma

T2 - Does It Matter?

AU - Kothari, Shalin

AU - Hillengass, Jens

AU - McCarthy, Philip L.

AU - Holstein, Sarah A.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose of Review: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. Recent Findings: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Summary: Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.

AB - Purpose of Review: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice. Recent Findings: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Treatment arms that are more effective from a PFS or overall response rate perspective are also associated with superior MRD negativity rates. The current standard MRD methodologies are limited by requiring bone marrow samples and refinement of methodologies that can detect disease outside of the bone marrow is needed. Summary: Currently, MRD is a prognostic biomarker and further efforts are required to determine whether it can serve as a surrogate endpoint. The use of MRD status to guide treatment decisions is currently not recommended outside the confines of a clinical trial.

KW - Minimal residual disease

KW - Multiple myeloma

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=85060624702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060624702&partnerID=8YFLogxK

U2 - 10.1007/s11899-019-0497-7

DO - 10.1007/s11899-019-0497-7

M3 - Review article

C2 - 30671912

AN - SCOPUS:85060624702

VL - 14

SP - 39

EP - 46

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -